Inhalable Mannosylated Rifampicin-Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy

• Main Authors: Juan M. Galdopórpora (Author), Camila Martinena (Author), Ezequiel Bernabeu (Author), Jennifer Riedel (Author), Lucia Palmas (Author), Ines Castangia (Author), Maria Letizia Manca (Author), Mariana Garcés (Author), Juan Lázaro-Martinez (Author), Maria Jimena Salgueiro (Author), Pablo Evelson (Author), Nancy Liliana Tateosian (Author), Diego Andres Chiappetta (Author), Marcela Analia Moretton (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Among respiratory infections, tuberculosis was the second deadliest infectious disease in 2020 behind COVID-19. Inhalable nanocarriers offer the possibility of actively targeting anti-tuberculosis drugs to the lungs, especially to alveolar macrophages (cellular reservoirs of the <i>Mycobacteri...